The Intravenous Immunoglobulin market is poised to grow strong during the forecast period 2017 to 2025
Some of the prominent trends that the market is witnessing include improving health care infrastructure across the globe, increasing number of chronic inflammatory demyelinating polyneuropathy (CIDP) patients and technological developments in the methods used for production and purification of IVIG products.
Based on therapeutic area the market is categorized into acute infections, immune deficiencies and autoimmune diseases. Furthermore Immune Deficiencies are divided into x-linked agammaglobulinemia, acquired compromised immunity conditions and hypogammaglobulinemia (primary immune deficiencies). Autoimmune Diseases are segmented into inflammatory diseases and immune thrombocytopenia (ITP).
Depending on product types the market is segregated by IGM, IGG, IGE, Immunoglobulin D (IGD) and IGA.
On the basis of plasma protein the market is bifurcated into albumin, factor IX, polyvalent IVIG, hyperimmunes (IM&IV) and factor VIII.
In terms of end user the market is segmented into home care, hospitals and clinics.
By application the market is classified into primary humoral immunodeficiency, immunodeficiency diseases, myasthenia gravis, hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), inflammatory myopathies, kawasaki disease, idiopathic thrombocytopenic purpura (ITP), guillain-barre syndrome (GBS), chronic lymphocytic leukemia, specific antibody deficiency (SAD), multifocal motor neuropathy, congenital AIDS and other applications.
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
4 Global Intravenous Immunoglobulin Market, By Therapeutic Area
5 Global Intravenous Immunoglobulin Market, By Product Type
6 Global Intravenous Immunoglobulin Market, By Plasma Protein
7 Global Intravenous Immunoglobulin Market, By End User
8 Global Intravenous Immunoglobulin Market, By Application
9 Global Intravenous Immunoglobulin Market, By Geography
10 Key Player Activities
11 Leading Companies
- Biotest AG
- Guizhou Taibang Biological Products Co.
- Baxter International Inc
- China Biologic Products, Inc
- Shanghai RAAS Blood Products Co., Ltd
- Grifols, S.A
- Beijing Tiantan Biological Products Co., Ltd
- Octapharma AG
- CSL Limited
- Hualan Biological Engineering Inc
- Kedrion Biopharma
- Biotest AG
- OMRIX Biopharmaceuticals Ltd
- LFB BIOTECHNOLOGIES
- BDI Pharma Inc
For more information about this report visit https://www.researchandmarkets.com/research/96kh5x/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Latest posts by Brad Bennett (see all)
- Panish Shea & Boyle LLP & PARRIS Law Firm Obtain Landmark $54 Million Verdict for Brothers Severely Injured in Head-on Collision with Big Rig - February 22, 2018
- When 80 Insurance CEOs Learned a Secret â€¦ - February 22, 2018
- Hyundai Celebrates World Debut of the All-New 2019 Santa Fe - February 22, 2018